Phase 3 N=121 Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes
Exercise-related Amenorrhea
Primary: Change in Lumbar Bone Mineral Density — 0.025; 0.008; 0.012 g/cm^2 — p=0.039
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=16 Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3
Stage IV Non-Small Cell Lung Cancer
Primary: Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung…
Phase 4 N=50 A Low Dose Remifentanil Infusion During Tracheal Extubation in Surgical Intensive Care Unit Patients
Tracheal Extubation
Primary: Mean Arterial Pressure Changes During Extubation — 94; 97; 96; 97 mmHg
Phase 3 N=524 Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Number of Subjects With Anti-vaccine Pneumococcal Serotypes Antibody Concentrations Greater Than or Equal to (≥) the Cut-off [Follow-up Period: Persistence Analysis in…
Phase 4 N=200 The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications
Postoperative Complications · Neuromuscular Blockade
Primary: Number of Participants With a Postoperative Pulmonary Complication — 33; 40 Participants
Phase 4 N=120 Subject Satisfaction With AbobutulinumtoxinA Treatment
Glabellar Frown Lines
Primary: Subject Satisfaction When Treated With abobutulinumtoxinA in Their Glabellar Lines — 66; 38; 4; 2 Participants
N/A N=211 TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051
Opioid Use Disorder
Primary: Days of Opioid Use — 6.8 days
Phase 4 N=150 Intravenous Lidocaine and Ketorolac for Pain Management
Pain
Primary: Pain Score at 30 Minutes — 5.52; 3.88; 3.14 score on a scale
N/A N=71 Evaluation of GERDOFF Efficacy in Combination With Proton Pump Inhibitor
Gastro-oesophageal Reflux Disease
Primary: Change From Baseline to Visit V4 of the Total Score of RSI Questionnaire — -16.2; -13.7 Score on a scale — p=0.276
N/A N=49 Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers
Nicotine Dependence
Primary: Percent Change in Binding Potential of Dopamine Release During PET Scan Post Amphetamine Administration — 14; 11.2; 1.9; 9.3 percentage change in binding potential
N/A N=25 Evaluation of Physician-based Decision Support
Type 1 Diabetes Mellitus · MDI · CGM
Primary: Percent of Time With Sensed Glucose 70-180 mg/dl — 58.8; 51.2; 59.3 percentage of time
Phase 4 N=60 Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period
Congenital Bleeding Disorder · Haemophilia A
Primary: Occurrence of Confirmed FVIII Inhibitor Development (≥ 0.6 BU) — 0; 0 Participants
N/A N=118 Care Coordination/Home Telehealth to Safeguard Care in CKD
Safety Issues · Chronic Kidney Disease
Primary: Safety Events — 70; 54; 61; 58 safety events
Phase 3 N=19,271 A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Primary: Composite of Cardiovascular (CV) Death, MI or Stroke — 736; 818 Number of participants with event — p=0.0378
Phase 3 N=365 Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Active Systemic Lupus Erythematosus
Primary: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 — 86; 57 Participants — p=0.0013